EffeKt Taiwan- Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Taiwan
The aim of this international prospective post-marketing surveillance study is to obtain data on treatment procedures, long-term safety and efficacy and patient acceptance of KOGENATE Bayer/FS in treatment of patients with haemophilia A under daily-life treatment conditions.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||EffeKt Taiwan- Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Taiwan|
- Efficacy and Safety of Kogenate FS [ Time Frame: After 12 months and after 24 months ] [ Designated as safety issue: Yes ]
|Study Start Date:||April 2009|
|Study Completion Date:||December 2011|
Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Patients under daily life treatment receiving Kogenate according to local drug information.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00932555
|Many Locations, Taiwan|
|Study Director:||Bayer Study Director||Bayer|